Bio Search, an unlisted Tokyo company that builds biosensing and medical devices, has agreed to acquire InnerEye Ltd., an Israeli company that analyses brain activity with artificial intelligence. Bio Search announced on November 9, 2026, that it had signed a share exchange agreement to buy all of InnerEye's shares and make it a wholly owned subsidiary.
The companies did not disclose the exchange ratio or put a value on the deal. Because it is a share exchange, InnerEye's shareholders are to receive Bio Search shares rather than cash. Completion depends on approvals from Israeli regulators and other conditions, and Bio Search expects it to happen between December 2026 and early January 2027.
InnerEye is based in Herzliya and is led by chief executive Uri Antman. The announcement did not say how many people work at InnerEye or whether any of them will move to Japan, but Bio Search said it plans a single management structure covering both countries.
What InnerEye built
InnerEye analyses electroencephalogram (EEG) signals, the electrical activity of the brain recorded through sensors, in real time. Its software is designed to tell apart the mental states involved when a person perceives something and makes a decision, and to learn from the brain activity of experts as they do their work.
The company calls its approach Minded A.I. A wearable brain-computer interface captures parts of an expert's judgment, which InnerEye then turns into material for training AI models. The idea is that a model can pick up some of what an experienced specialist notices, and that the same technology can help less experienced workers or automate parts of expert tasks.
InnerEye sells this through two products. Sense.I combines expert decisions with AI to train and tune models, and the company's website claims it can make model learning up to 15 times faster while improving accuracy and lowering implementation costs. Sense Plus looks at the cognitive and emotional factors behind people's actions, including fatigue, concentration and attention, and is aimed at organisations that want to understand and develop their experts' skills.
Why Bio Search is buying
Bio Search was founded in October 2018 and has capital of ¥350 million (about $2.2 million). It develops and sells biosensing devices and medical equipment and runs a data analysis platform that handles EEG, electrocardiogram, heart rate and muscle activity (EMG) data.
The company said that putting InnerEye's brain-signal technology together with its own sensing hardware, medical device development and presence in Asian markets would give it a global platform for healthcare, brain technology and cognitive AI. Pooling EEG data with the other biological signals it collects is supposed to make the AI more precise and robust and to widen what it can be used for, according to Unite.AI, although Bio Search did not put numbers on those gains.
The areas it named include cognitive assessment and support for early diagnosis in healthcare, industrial automation, emotion computing, security and tools that help experts make decisions. In the Japanese-language release, Antman described Bio Search as the best partner for taking InnerEye's technology to commercial scale worldwide, while Bio Search's chief executive said the combination would create a platform unlike any other for brain and life sciences research and for healthcare.
The founders
InnerEye was founded in 2014 by two academics, according to Unite.AI. Amir Geva is a professor of electrical and computer engineering at Ben-Gurion University of the Negev. Leon Deouell is a physician and professor of brain sciences at the Hebrew University of Jerusalem. The release described the company as built on the combined research of the two.
Neither company disclosed how much money InnerEye has raised, who its investors are or what revenue it brings in. Bio Search also did not disclose its own revenue or headcount.
A plan for a Nasdaq listing
Bio Search presented the acquisition as a step toward listing on Nasdaq in 2028. Along with the unified leadership team for Japan and Israel, it said it would strengthen governance and internal controls across the group.
The deal had not closed at the time of the announcement. Bio Search did not describe any changes to InnerEye's Sense.I or Sense Plus products, or say what will happen to InnerEye's existing customer contracts once the share exchange is completed.




